Abstract 3239: Discovery and biological characterization of ON108600, a small molecule inhibitor of protein kinase CK2.

Abstract

Abstract Protein kinase CK2 (Casein kinase 2) is a highly conserved, constitutively active Ser/Thr protein kinase implicated in cellular transformation and tumorigenesis. CK2 regulates multiple oncogenic pathways involved in cell cycle progression, suppression of apoptosis, hypoxia, angiogenesis, inflammation and DNA repair. Unlike other signaling molecules such as PI3K, RAF, RAS, where genetic alterations lead to deregulated signaling pathways, in the case of CK2, only its high expression levels have been associated with a disease state and no mutations have been found to date. Here we describe the mechanism of action of ON108600 a potent small molecule inhibitor of both catalytic subunits of protein kinase CK2. ON108600 showed broad-spectrum anti-proliferative and cytotoxic activity in multiple cancer cell lines while having little or no effect on normal cells. CK2 regulates Akt signaling through phosphorylation and inactivation of PTEN and via direct and specific phosphorylation of Akt at S129. Treatment with ON108600 resulted in dramatic reductions of phosphorylation of PTEN and Akt S129 and downstream targets of Akt in multiple cancer cell lines. Further, phosphorylation of p21Cip1/Waf1 at Thr145 and its cytoplasmic localization has been shown to be a poor prognostic marker in breast cancer. ON108600 showed a dose and time dependant dephosphorylation of p21 at Thr145 and induced a potent mitotic cell cycle arrest in most cancer cell lines. CK2 has also been implicated in regulating Caspase signaling via phosphorylation of caspase cleavage sites and thus exerting its pro-survival effects. ON108600 treatment induced potent apoptosis by activating the Caspase 3/7 signaling cascade. To understand the structural basis of CK2 inhibition by ON108600 we performed x-ray crystallographic studies of ON108600-CK2. The co-crystal structure of ON108600-CK2 revealed that ON108600 binds in the active site pocket of CK2α wherein it mimics the binding of GTP in the CK2 active site. Structural studies also revealed that ON108600 induces a conformational change in the β4-β5 loop of the catalytic subunit which is known to interact with the β-regulatory subunit of CK2 and critical for substrate recognition and activation. CK2α has been reported to be a structural microtubule associated protein and the CK2 holoenzyme has been shown to regulate microtubule dynamics. Interestingly, ON108600 was found to inhibit CK2 holoenzyme mediated polymerization of β-tubulins in in-vitro assays. CK2 has emerged as novel druggable target and selective inhibitors of CK2 such as ON108600 may prove as a potential anti-cancer therapy. Our ongoing studies are focused towards identifying novel combinations of ON108600 with existing chemotherapeutic agents in multiple myeloma, prostate and breast cancer. Citation Format: Amol Padgaonkar, Olga Rechkoblit, Stephen Cosenza, Venkat R. Pallela, Venkata Subbaiah DRC, MV Ramana Reddy, Aneel Aggarwal, E Premkumar Reddy. Discovery and biological characterization of ON108600, a small molecule inhibitor of protein kinase CK2. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3239. doi:10.1158/1538-7445.AM2013-3239 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.